Куросърф

Куросърф (Poractant Alfa) is a natural surfactant used to treat respiratory distress syndrome in newborns. This medication helps improve lung function by reducing surface tension in the alveoli. Suitable for preterm infants requiring endotracheopulmonary support.

Poractant Alfa is primarily used to manage respiratory distress syndrome (RDS) in premature infants. It works by replacing deficient natural surfactant in the lungs, aiding breathing and reducing complications. This medication is administered directly to the lungs via endotracheopulmonary route.

Poractant Alfa helps restore lung compliance by lowering surface tension in the alveoli, making it easier for infants to breathe. It may temporarily improve oxygenation and reduce the need for mechanical ventilation. Effects are typically observed shortly after administration.

Poractant Alfa should only be administered by trained healthcare professionals in a clinical setting. Monitor infants closely for signs of adverse reactions, such as bradycardia or oxygen desaturation, during and after administration. Ensure proper storage and handling to maintain sterility.

No significant drug interactions have been reported with Poractant Alfa. However, caution is advised when used alongside other medications affecting lung function. Always inform healthcare providers of all medications being administered to the infant.